Coronavirus company news summary - Achiko secures approval for emergency use of rapid test in Indonesia - Rako Science to offer saliva test for vulnerable communities in New Zealand - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Achiko secures approval for emergency use of rapid test in Indonesia – Rako Science to offer saliva test for vulnerable communities in New Zealand

25 Aug 2021

Swiss company Achiko, via its subsidiary PT Achiko Medika Indonesia, has received product and registration emergency use approval for its DNA aptamer-based rapid test, AptameX, for Covid-19 in Indonesia. The Indonesian Ministry of Health has also approved the test’s sister digital passporting service, Teman Sehat (Health Buddy). PT Achiko Medika Indonesia and PT Indofarma TBK have signed an agreement to produce the cost-effective Covid-19 test and obtained product registration approval in the country.

Rako Science has partnered with non-profit organisation Whānau Waipareira to provide its COVID-19 PCR saliva test for vulnerable communities in New Zealand. The test, which was developed by the University of Illinois, will be deployed at Waipareira’s community testing centre to help protect asymptomatic individuals. The saliva test is non-invasive and observed to be at least as precise as nasopharyngeal swab tests in detecting Covid-19.

Healthcare technology firm Medivolve is set to introduce mobile vans for Covid-19 testing in a bid to boost on-site testing for schools, workplaces and events. The mobile testing vans will have the required testing equipment, supplies and technology for patient registration. Meant to enable early detection of the disease, the new service covers rapid antigen and antibody tests, and PCR tests that deliver results in 15 minutes, and two to ten business days, respectively. The first two mobile testing vans will be launched in Las Vegas, Nevada, US.